RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices
December 16 2019 - 8:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced that the Company will be
added to the Russell 2000® and Russell Microcap® Indices as a part
of the Russell quarterly update, effective December 23, 2019.
The Russell 2000® Index measures the performance of
the small-cap segment of the U.S. equity market, while membership
in the Russell Microcap® Index measures the performance of the
micro-cap segment. Membership in the Russell 2000 and Microcap
Indices also provides automatic inclusion in the appropriate growth
and value style indices. Both the Russell 2000 and Russell Microcap
Indices roll up into the Russell 3000® Index, which measures the
performance of the 3,000 largest publicly-traded U.S. companies
based on market capitalization.
“We are delighted to be added to the Russell
indices only two months after our initial public offering,”
said Brian Wong, M.D., Ph.D., President and Chief Executive
Officer of RAPT Therapeutics. “Our addition to these indices
will further expand awareness of RAPT to the broader investment
community.”
The Russell U.S. Indices are widely used by global
investment managers and institutional investors for index funds and
as benchmarks for active investment strategies. Approximately $9
trillion in assets are benchmarked against Russell U.S. Indices.
Russell U.S. Indices are part of FTSE Russell, a leading global
index provider.
About RAPT Therapeutics,
Inc.RAPT Therapeutics (formerly FLX Bio) is a
clinical stage immunology-based biopharmaceutical company focused
on discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases. Utilizing its proprietary discovery and
development engine, the company is developing highly selective
small molecules designed to modulate the critical immune responses
underlying these diseases. In its first four years since inception,
RAPT has discovered and advanced two unique drug candidates, each
targeting C-C motif chemokine receptor 4. The Company’s lead
oncology drug candidate, FLX475, reached the clinic in just two and
a half years and RPT193, RAPT’s lead inflammation drug candidate,
is also in the clinic. The Company is also pursuing a range of
targets, including general control nonderepressible 2 and
hematopoietic progenitor kinase 1, that are in the discovery stage
of development.
Forward-Looking StatementsThis
press release contains forward-looking statements. These statements
relate to future events and involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future performances or achievements expressed or implied by the
forward-looking statements. Each of these statements is based only
on current information, assumptions and expectations that are
inherently subject to change and involve a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements about RAPT’s expected addition to the
Russell 2000® and Russell Microcap® Indices. Detailed information
regarding factors that may cause actual results to differ
materially from the results expressed or implied by statements in
this press release may be found in RAPT’s quarterly report on Form
10-Q filed with the Securities and Exchange Commission on December
11, 2019 and subsequent filings made by RAPT with the Securities
and Exchange Commission. These forward-looking statements speak
only as of the date hereof. RAPT disclaims any obligation to update
these forward-looking statements.
Media Contact: Angela Bittingmedia@rapt.com (925)
202-6211
Investor Contact: Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024